As of the latest Form 4 filed Jul 9, 2026.
What Disc Medicine Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 32 most recent filings for IRON.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | Yu Jonathan Yen-Wen Chief Operating Officer | SSale | −100.00 | $82.50 | $8.25K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | Yu Jonathan Yen-Wen, Chief Operating Officer | MExercise | +100.00 | $13.50 | $1.35K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Khara Rahul Chief Legal Officer | SSale | −1.65K | $75.00 | $124K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-29 | Khara Rahul, Chief Legal Officer | MExercise | +1.65K | $14.69 | $24.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Khara Rahul, Chief Legal Officer | SSale | −851.00 | $75.00 | $63.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Khara Rahul, Chief Legal Officer | MExercise | +851.00 | $14.69 | $12.5K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Yu Jonathan Yen-Wen Chief Operating Officer | SSale | −300.00 | $72.50 | $21.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-30 | 2026-06-26 | Yu Jonathan Yen-Wen, Chief Operating Officer | MExercise | +300.00 | $13.50 | $4.05K | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | Yu Jonathan Yen-Wen Chief Operating Officer | SSale | −9.70K | $72.66 | $705K | Yes (planned) | Form 4 ↗ |
| 2026-06-24 | 2026-06-22 | Yu Jonathan Yen-Wen, Chief Operating Officer | MExercise | +9.70K | $13.50 | $131K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Khara Rahul Chief Legal Officer | SSale | −500.00 | $71.62 | $35.8K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Khara Rahul, Chief Legal Officer | SSale | −1.60K | $70.73 | $113K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Khara Rahul, Chief Legal Officer | SSale | −5.40K | $69.94 | $378K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Khara Rahul, Chief Legal Officer | MExercise | +7.50K | $14.69 | $110K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Quisel John D Chief Executive Officer | SSale | −1.55K | $71.61 | $111K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Quisel John D, Chief Executive Officer | SSale | −9.52K | $70.70 | $673K | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Quisel John D, Chief Executive Officer | SSale | −22.9K | $69.92 | $1.60M | Yes (planned) | Form 4 ↗ |
| 2026-06-23 | 2026-06-18 | Quisel John D, Chief Executive Officer | MExercise | +34.0K | $9.86 | $335K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-16 | Yu Jonathan Yen-Wen Chief Operating Officer | SSale | −6.96K | $69.92 | $487K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-16 | Yu Jonathan Yen-Wen, Chief Operating Officer | SSale | −11.7K | $68.76 | $801K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-16 | Yu Jonathan Yen-Wen, Chief Operating Officer | MExercise | +13.4K | $9.86 | $132K | Yes (planned) | Form 4 ↗ |
| 2026-06-18 | 2026-06-16 | Yu Jonathan Yen-Wen, Chief Operating Officer | MExercise | +5.26K | $9.86 | $51.9K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-14 | Franchi Jean M. Chief Financial Officer | SSale | −6.26K | $69.24 | $433K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Savage William Jacob Chief Medical Officer | SSale | −2.20K | $66.81 | $147K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Savage William Jacob, Chief Medical Officer | SSale | −3.53K | $66.12 | $233K | Yes (planned) | Form 4 ↗ |
| 2026-04-15 | 2026-04-13 | Franchi Jean M. Chief Financial Officer | SSale | −400.00 | $69.00 | $27.6K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Savage William Jacob Chief Medical Officer | SSale | −2.99K | $66.41 | $198K | Yes (planned) | Form 4 ↗ |
| 2026-03-04 | 2026-03-02 | Savage William Jacob, Chief Medical Officer | SSale | −4.39K | $65.52 | $288K | Yes (planned) | Form 4 ↗ |
| 2026-02-27 | 2026-02-25 | Franchi Jean M. Chief Financial Officer | SSale | −353.00 | $69.06 | $24.4K | Yes (planned) | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | White William Richard Director | SSale | −39.00 | $29.11 | $1.14K | Yes (planned) | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | White William Richard, Director | SSale | −162.00 | $28.52 | $4.62K | Yes (planned) | Form 4 ↗ |
| 2024-05-03 | 2024-05-01 | White William Richard, Director | MExercise | +201.00 | $9.86 | $1.98K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also IRON’s full analysis or the market-wide insider trading feed. The tabs above jump to IRON’s other SEC data.
Source: SEC Form 4 filings for IRON, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.